Media coverage about EXACT Sciences (NASDAQ:EXAS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EXACT Sciences earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.7683963472666 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s rankings:
- Exact Sciences finds winning combo in Jerry Kelly and the PGA Tour Champions (finance.yahoo.com)
- Today’s Hot Stock Under Review – Exact Sciences Corporation (NASDAQ: EXAS) – Alpha Beta Stock (alphabetastock.com)
- Here’s Why Exact Sciences Shares Fell 10.3% in February (finance.yahoo.com)
- Here's Why Exact Sciences Shares Fell 10.3% in February (finance.yahoo.com)
- Mayo Clinic’s Dr. Paul Limburg to join Exact Sciences medical leadership – Markets Insider (markets.businessinsider.com)
Shares of EXACT Sciences (NASDAQ:EXAS) traded up $1.27 during trading hours on Friday, reaching $52.15. 4,048,749 shares of the company were exchanged, compared to its average volume of 2,740,000. The company has a market capitalization of $6,400.00, a PE ratio of -25.56 and a beta of 0.71. EXACT Sciences has a 12-month low of $19.91 and a 12-month high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.15 and a quick ratio of 6.77.
Several analysts have issued reports on the stock. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Robert W. Baird raised shares of EXACT Sciences from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $42.56 to $56.00 in a research note on Tuesday, February 27th. Leerink Swann set a $67.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Benchmark downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. EXACT Sciences presently has an average rating of “Buy” and a consensus target price of $52.84.
In related news, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now directly owns 37,558 shares in the company, valued at $1,973,297.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Graham Peter Lidgard sold 39,884 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $43.10, for a total transaction of $1,719,000.40. The disclosure for this sale can be found here. Insiders sold 547,463 shares of company stock valued at $27,045,199 over the last quarter. 4.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) Receiving Somewhat Favorable Media Coverage, Study Finds” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3254237/exact-sciences-exas-receiving-somewhat-favorable-media-coverage-study-finds.html.
About EXACT Sciences
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.